Open Access

Identification of Plasmodium falciparum specific translation inhibitors from the MMV Malaria Box using a high throughput in vitro translation screen

  • Vida Ahyong1,
  • Christine M. Sheridan1,
  • Kristoffer E. Leon1,
  • Jessica N. Witchley2,
  • Jonathan Diep1 and
  • Joseph L. DeRisi1, 3Email author
Malaria Journal201615:173

Received: 14 January 2016

Accepted: 11 March 2016

Published: 17 March 2016



A major goal in the search for new anti-malarial compounds is to identify new mechanisms of action or new molecular targets. While cell-based, growth inhibition-based screening have enjoyed tremendous success, an alternative approach is to specifically assay a given pathway or essential cellular process.


Here, this work describes the development of a plate-based, in vitro luciferase assay to probe for inhibitors specific to protein synthesis in Plasmodium falciparum through the use of an in vitro translation system derived from the parasite.


Using the Medicines for Malaria Venture’s Malaria Box as a pilot, 400 bioactive compounds with minimal human cytotoxicity profiles were screened, identifying eight compounds that displayed greater potency against the P. falciparum translation machinery relative to a mammalian translation system. Dose–response curves were determined in both translation systems to further characterize the top hit compound (MMV008270).


This assay will be useful not only in future anti-malarial screening efforts but also in the investigation of P. falciparum protein synthesis and essential processes in P. falciparum biology.


Translation Ribosome Anti-malarials Screen Plasmodium falciparum MMV Malaria Box


Identifying new anti-malarials with novel mechanisms of action is a key goal in the fight to eradicate malaria worldwide [1]. A common and very successful strategy relies on screening in vitro cultures of Plasmodium falciparum against large compound collections and assaying for growth inhibition in a ‘top-down’ approach to drug discovery. Using this type of approach can result in the subsequent identification of drug targets by selection of resistant strains and whole genome sequencing of these resistant strains to identify mutations (i.e., single nucleotide polymorphisms, copy number variants, insertions/deletions) that confer resistance [24]. However, one challenge with this approach is the high likelihood of encountering new compounds associated with targets that have previously been exploited as opposed to identifying new mechanisms of action. This has certainly been the case in recent instances, in which multiple groups have identified diverse chemical compounds that all have the same molecular determinants of resistance, such as PfATP4, and quite possibly the same mechanism of action [2, 5, 6] .

The complementary strategy is to narrow the search criteria by assaying for activity against a specific biological function or pathway. For example, this approach was used to identify a specific inhibitor of PfIspD, an enzyme essential for isoprenoid synthesis, by counter screening with growth media supplemented with isopentenyl pyrophosphate (IPP), thus narrowing hits to only those active against apicoplast targets (such as isoprenoid enzymes) [4]. Facilitating these efforts, the freely available Medicines for Malaria Venture (MMV) Malaria Box has been a welcome resource, providing biologically active compounds with unknown targets and mechanisms of action [7]. The library contains 400 chemically diverse compounds that are commercially available and pre-screened for activity in the blood stages of P. falciparum with minimal human cytotoxicity.

Among the possible pathways that can be functionally assayed, protein synthesis represents an attractive target, given its absolutely essential nature. Indeed, despite the fact that P. falciparum is a eukaryotic organism, there are ample differences between the P. falciparum and mammalian ribosomes that could be plausibly exploited [8, 9]. In fact, precedence for this type of inhibition of protein synthesis was exemplified in the discovery of the sordarin class of natural products which selectively inhibits fungal protein synthesis by inhibiting the yeast eukaryotic elongation factor 2 [10]. In a similar manner, a potent new compound, DDD107498, was reported to specifically inhibit P. falciparum protein synthesis by blocking activity of the P. falciparum translation eukaryotic elongation factor 2 [11]. Here, this study reports the use of a P. falciparum in vitro translation assay, amenable to plate-based screening, to identify inhibitors of P. falciparum translation present in the Malaria Box.


Plasmodium falciparum culturing

W2 strains were maintained in HYPERFlasks (Corning, Corning, NY, USA) in 500 mL RPMIc [RPMI 1640 media supplemented with 0.25 % Albumax II (GIBCO, Grand Island, NY, USA), 2 g/L sodium bicarbonate, 25 mM HEPES (pH 7.4), 0.1 mM hypoxanthine, and 50 ug/L gentamycin] in a 37 °C, 5 % O2, 5 % CO2 incubator in 2 % haematocrit (HC). Cells were synchronized with 5 % sorbitol treatment for two generations to achieve high synchronicity.

Harvesting cell pellets

One liter parasite cultures grown in two 500 mL HYPER flasks were harvested in the late trophozoite stage at approximately 15 % parasitaemia by centrifugation for 5 min at 1500×g at room temperature and 0.06 % final saponin in Buffer A (20 mM HEPES pH 8.0, 2 mM Mg(OAc)2, 120 mM KOAc). Saponin lysed pellets were centrifuged at 4 °C 10,000×g for 10 min and washed once with ice-cold Buffer A. The pellet was resuspended in 2 mL of Buffer B2 [20 mM HEPES pH 8.0, 100 mM KOAc, 0.75 mM Mg(OAC)2, 2 mM DTT, 20 % glycerol, 1× protease inhibitor cocktail (Roche)], flash frozen, and stored in −80 °C freezer until the sample was ready to homogenize.

Homogenization of cell pellets

Frozen pellets were thawed on ice and added to a 3-mL luer lock syringe, locked onto a pre-chilled cell homogenizer (Isobiotec, Germany) on ice and passed between two syringes 20 times. Lysate was centrifuged at 4 °C 16,000×g for 10 min and the supernatant was stored at −80 °C.

In vitro translation assay

Plasmodium in vitro translation reactions were carried out v-bottom 96-well PCR plates (USA Scientific, Ocala, FL, USA) and sealed with adhesive aluminum foil plate seals (Beckman Coulter, Indianapolis, IN, USA) with the following components in 20 μL: 16 μL lysate, 1 μg T7 transcribed firefly luciferase mRNA, 10 µM amino acid mixture, 20 mM HEPES/KOH pH 8.0, 75 mM KOAc, 2 mM Mg(OAc)2, 2 mM DTT, 0.5 mM ATP, 0.1 mM GTP, 20 mM creatine phosphate, 0.2 μg/μl creatine kinase for 0.5–1.5 h at 37 °C. All liquid dispensing was performed using Rainin E4 12-channel electronic pipettes (Rainin Instruments, Oakland, CA, USA). After incubation, the reactions were quenched with a final concentration of 5 µM cycloheximide. Samples were transferred to a 96-well LUMITRAC 200 white immunology plate (Greiner Bio-One, Monroe, NC, USA). Reactions were assayed using the Promega GloMax-Multi + microplate reader with a three-second delay and ten-second integration after addition of 100 μL luciferin reagent (20 mM Tricine, 2.67 mM MgSO4×7H2O, 0.1 mM EDTA, 33.3 mM DTT, 530 μM ATP, 270 μM Acetyl CoEnzyme A, 1 mM D-Luciferin, 265 μM Magnesium Carbonate Hydroxide, pH 8.15).

Rabbit reticulocyte (Retic Lysate IVT Kit, Thermo Fisher Scientific, Waltham, MA, USA) in vitro translation assays were carried out with the following components in 20 μL: 0.5 μL 20× translation mix minus methionine, 0.5 μL 20× translation mix minus leucine, 1 μg T7 transcribed firefly luciferase mRNA, and 18 μL reticulocyte lysate for 5–20 min at 37 °C. After incubation, the reactions were quenched with 5 µM cycloheximide and assayed in the same manner as the Plasmodium lysates.

Drug screening

The open-access Malaria Box was obtained from MMV. Initial screens were performed at 1 μM final drug concentration in v-bottom 96-well PCR plates (USA Scientific, Ocala, FL, USA) and sealed with adhesive aluminum foil plate seals (Beckman Coulter, Indianapolis, IN, USA). The 20 μL reaction contained the following components in 20 μL: 14 μL lysate, 1 μg T7 transcribed firefly luciferase mRNA, 10 µM amino acid mixture, 20 mM HEPES/KOH pH 8.0, 75 mM KOAc, 2 mM Mg(OAc)2, 2 mM DTT, 0.5 mM ATP, 0.1 mM GTP, 20 mM creatine phosphate, 0.2 μg/μl creatine kinase. After the 1.5 h incubation, samples were immediately quenched using 2μL of 50 μM cycloheximide stop solution and then transferred to the Lumitrac assay plate using 12-channel electronic pipettes and assayed in the same manner described in the above in vitro translation assay. IC50 values were determined with a constant 2.5 % DMSO, using a 12-point 1:3 titration starting at 250 μM. Data were normalized to background and DMSO-only controls.


Development of a high-throughput, malaria-specific, in vitro translation assay

Building upon the work of Ferreras et al., an in vitro translation assay was further developed and optimized from P. falciparum cultures with the addition of exogenous firefly luciferase reporter mRNAs to allow for high-throughput plate-based luciferase assay screening (Fig. 1a) [12]. Cultures were scaled up to 500 ml HYPERFlasks (Corning) using synchronized, high-density, late trophozoite cultures, and utilized a saponin lysis method to release the parasites from the red blood cells (see “Methods” section). To maintain consistency of lysis conditions, a cell homogenizer (Isobiotec, Germany) was utilized, which gently and uniformly breaks open cells by passing the lysate though a precise 4-µM ball-bearing clearance, a technique that has found widespread use in sub-cellular fractionation studies [13]. Harvesting higher parasitaemia cultures in small lysis buffer volumes resulted in robust and reproducible translation activity when the A280 measured in the range of 7–20 mg/mL. Lysate competency for in vitro translation was measured by the translation of the firefly luciferase reporter constructs with a P. falciparum 5′ untranslated region (UTR) of the ubiquitously expressed erythrocyte binding antigen (EBA-175) and a 3′UTR from the P. falciparum histidine rich protein (Pf HRP) (Fig. 1b). These extracts achieved luciferase saturation similar to commercially available rabbit reticulocyte lysate (Retic Lysate IVT, Thermo Fisher Scientific), although with slower kinetics (Fig. 1c). To verify that the activity of the lysates did not result from the negligible amount of ribosome-containing reticulocytes potentially present in red blood cell (RBC) cultures, lysates were isolated from uninfected RBC cultures. To attain a comparable concentration of material (as measured by A280) from the uninfected RBCs (uRBCs) to the P. falciparum lysates, uRBCs were concentrated 10-fold using a Centricon YM-10 spin column (EMD Millipore, Hayward, CA, USA) and the in vitro translation assay was performed in an identical manner with a simultaneously prepared P. falciparum lysate in the presence or absence of magnesium (Additional file 1). Concentrated uRBCs were unable to produce luciferase activity, indicating that the magnesium-dependent translation activity in this assay is exclusively due to the presence of P. falciparum ribosomes and not from residual human ribosomes present in RBCs. Each batch of P. falciparum lysate varies in terms of maximum luciferase output and time to reach that maximum. Thus, for each harvest, a preliminary kinetic assay is necessary to establish the optimal incubation time (defined as ~80 % of maximum translational activity).
Fig. 1

Development of a luciferase based in vitro translation assay in Plasmodium falciparum. a Workflow for preparing lysate for in vitro translation assay. b Plasmid construct to generate mRNA transcripts containing a P. falciparum specific 5′ and 3′ UTR with a firefly luciferase open reading frame. Maxipreps of the plasmid were digested with PvuII and BamHI to create the templates for T7 transcription to make a final mRNA with the P. falciparum UTRs and firefly luciferase. c Lysates were incubated in the presence of a 10 × magnesium-containing translation buffer and luciferase mRNAs for a time course of 30 min to 120 min followed by the addition of luciferin reagent to assay for luciferase activity. d Lysates were incubated with DMSO control only or with 5 μM cycloheximide before or after the 120-min incubation followed by assaying for luciferase output

To verify that this assay specifically measures protein synthesis, translation activity of the lysate was assessed in the presence of 5 μM cycloheximide (27× reported IC50 = 181 nM) [14], an inhibitor of general eukaryotic translation elongation. When cycloheximide is added prior to the 37 °C incubation, translation is inhibited, resulting in the absence of luciferase expression, however, when added following the 37 °C incubation there was no effect on translation and the final luciferase activity was comparable to a control DMSO sample (Fig. 1d). Furthermore, to confirm that the assay is specific for inhibitors of protein synthesis, and not general anti-malarial activity, several anti-malarial compounds at 1-μM concentration (dihydroartemisinin (DHA), piperaquine, chloroquine, SJ579, and quinine) were tested along with 1-μM cycloheximide and found that none significantly inhibited translation in the assay with the exception of cycloheximide (Fig. 2a). Additionally, in both the 1-μM and 5 μM cycloheximide concentrations, in every lysate assayed, the measured luciferase activity was equivalent to the background (see Fig. 1d and Additional file 1).
Fig. 2

In vitro translation assay drug screens. a Lysates were incubated in the presence of anti-malarials and cycloheximide, a general eukaryotic translation inhibitor, all at 1 μM final concentration. Error bars represent the standard deviation among three biological replicates. b MMV Malaria Box compounds were added to lysates at a 1 μM final concentration. The average of three biological replicates were used to determine the extent of translation inhibition and normalized to the average of the DMSO controls present in each plate. Each point on the graph is the averaged response of a single drug. Each point is colour-coded by type of effect: top hit compound, no P. falciparum inhibition, high standard deviation, or inhibition in rabbit reticulocyte. The histogram on the right of the graph displays the total percentage of compounds with the given luciferase ratio

Screening the MMV Malaria Box for translational inhibitors

Screening of the Malaria Box was performed using a 1-µM drug concentration for 1.5 h at 37 °C using the existing layout of the Malaria Box. Each plate was replicated at least three times and normalized to the average of all the control wells situated at the peripheral columns of each plate, totaling 16 controls wells per plate. A stop solution of 5 μM cycloheximide was added immediately following the incubation to simultaneously stop all translation in all wells, providing for uniform temporal measurements of translation throughout the luminescence assay. The results of this screen were calculated as a fractional value of the maximum in vitro translation normalized to the average of DMSO controls (Fig. 2b). Standard high throughput screen assay parameters were calculated (Additional file 2) and resulted in a signal-to-noise ratio of >3000, a coefficient of variation of 20.12 % and a Z’ factor of 0.87. Of all 400 wells assayed, 88.5 % (n = 354) of the compounds showed little to no inhibitory effect on translation (normalized luciferase ratio >0.80) whereas 46 compounds showed at least a 20 % inhibition of luciferase activity. To be considered further, a conservative cut-off was imposed for the standard deviation between replicates to be less than 0.20 of the normalized luciferase ratio of each sample. Although the Malaria Box was previously screened for cytotoxic effects, a secondary screen was performed on the final 15 compounds (standard deviation of <0.20 and >20 % normalized luciferase inhibition) using commercially available rabbit reticulocyte lysate (also in 1 μM drug concentration with two replicates) to ensure that positive hits did not also block mammalian in vitro translation or inhibit luciferase activity (Retic IVT, Life Technologies). A specificity index was defined as the ratio of normalized rabbit reticulocyte average translation over the normalized P. falciparum average translation. Specificity ratios ranged from 0.42 to 2.14, with values >1 signifying compounds that have a greater inhibitory effect on P. falciparum translation than rabbit reticulocyte translation, a proxy for general mammalian translation. After filtering for P. falciparum inhibition, standard deviation, rabbit reticulocyte inhibition, and large specificity ratios, eight compounds were identified for further analysis (Fig. 3). These eight compounds showed a ratio of >1.2 and are promising hits for further optimization and lead development. The top hit compound, MMV008270, had a specificity ratio of 1.96 and inhibited P. falciparum in vitro translation by >70 % on average when assayed at 1uM drug concentration. Next, dose–response curves of MMV008270 were characterized to calculate the half-maximal inhibitory concentration (IC50) value in both the P. falciparum and rabbit reticulocyte systems. Dose–response assays were performed in duplicate, with a 12-point 1:3 dilution series starting at a high concentration of 250 μM (Fig. 4). The resulting IC50 value for P. falciparum was 263 nM whereas the IC50 value for rabbit reticulocyte was 494 nM, a 1.89× higher IC50 value and consistent with the initial specificity index of 1.96× higher translation inhibition from the initial Malaria Box screen. The CHEMBL MMV databases were inspected for bioassays results of this compound. A listed Novartis study on the cytotoxicity in human fibroblasts calculates an IC50 for this compound above 32 μM suggesting low in vivo activity or penetrance in mammalian cells (Table 1) [15]. Additionally, an analogue (MMV006937) of the hit compound included in the Malaria Box set differs by the presence of a single hydrogen bond on the benzene ring and did not inhibit translation in the in vitro assay (% normalized luciferase translation MMV006937 = 83 %), suggesting a high degree of structural specificity associated with the inhibitory activity of the original hit. Further structure activity relationship studies of this compound will focus on the development of more specific and potent inhibitors of P. falciparum translation relative to a mammalian counterpart.
Fig. 3

Flow diagram and results of the Malaria Box screen. Starting with 400 compounds, each compound was tested in three independent biological replicates in in vitro translation assays with 1 μM of the compound. Of the 46 compounds that achieved at least 20 % inhibition of translation, only eight passed both the standard deviation filter, and specificity filter removing general eukaryotic translation inhibitors (as measured by translation inhibition in rabbit reticulocyte lysate) and luciferase inhibitors. ah Structures of the eight compounds that passed the primary and secondary screens. The letter of each structure is matched to the compounds listed in Table 1

Fig. 4

Dose–response curves of MMV008270. Dose-response curves in P. falciparum lysate or rabbit reticulocyte lysate using a 12-point 1:3 titration starting at 250 μM. Data were normalized to background and DMSO-only controls. IC50 values for each system are listed below the graph

Table 1

Eight top hit compounds

Chemical structure


MMV number

Alternative compound number

Average Pf IVT

Specificity index


CHEMBL IC50 in human fibroblast (MRC-5) cells to measure toxicity








>32000 nM








>32000 nM








>32000 nM








>32000 nM








>32000 nM







0.53; 0.75

>32000 nM








=19329.43 nM







0.41; 1.13

>32000 nM

After filtering for several attributes, this study offers a final list of eight hit compounds. The chemical structure letter corresponds to the structures found in Fig. 3. Listed in this Table are the CHEMBL names, MMV number, any alternative compound name found in databases, the average normalized luciferase output, specificity index, the CHEMBL IC50, and CHEMBL cytotoxicity IC50 data from human fibroblast (MRC-5) cells


This work presents a novel high-throughput luciferase assay that enables the discovery of compounds inhibiting eukaryotic protein synthesis in P. falciparum. This cell-free system is sensitive to the known translation inhibitor cycloheximide, whereas anti-malarials with no known effect on translation, such as chloroquine and DHA, do not exhibit inhibitory activity in the assay. Utilizing this novel assay resulted in the identification of eight compounds that are inhibitors of P. falciparum translation, and more effectively inhibit P. falciparum than mammalian in vitro translation. Considering that this assay is based on a crude extract that naturally has more variability than a pure enzyme assay, additional secondary screening (such as IC curves in this case) is required to establish their validity. Of these eight compounds, further characterization of the top hit, MMV008270, showed 1.9× higher activity against P. falciparum translation over a general eukaryotic translation system. While a 1.9× difference is likely to be too narrow for serious consideration as a lead molecule, it provides a starting point for further structure activity relationship studies with the goal of widening the gap between P. falciparum and mammalian inhibition. Further, target validation by selection for resistance may aid in determining which component of the ribosomal machinery is the target of this compound. It is likely that multiple components of the ribosome could be targeted simultaneously to yield a synergistic effect.

The assay developed here has the potential to be a powerful tool for additional translation-specific drug screens as well as answering important questions of basic Plasmodium biology. For example, future experiments using this streamlined, multi-well, plate-friendly assay will allow for the further investigation of cis-acting determinants of translational efficiency that were identified in a previous study [16]. In total, this work presents a valuable molecular tool for probing an essential process in P. falciparum biology.

Availability of supporting data

The data set supporting the results of this article will be freely available in the CHEMBL MMV repository (


Authors’ contributions

VA and JLD conceived and designed the study. VA, CMS, KEL, JNW, JD, and JLD performed experiments and analysed the data. VA, CMS and JLD drafted or revised the paper. All authors read and approved the final manuscript.


We thank members of the DeRisi Laboratory for thoughtful discussions and culturing assistance, especially Daniel Ebert, Wesley Wu, Florence Caro, and Ellen Yeh. JLD and this work were supported by the Howard Hughes Medical Institute. VA and JNW were supported by the NIH T32 Grant GM007810. CMS was supported by the UCSF Discovery Fellows Program. KEL and JD were supported by the HHMI Extraordinary Research Opportunities Program (ExROP).

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Biochemistry and Biophysics, University of California San Francisco
Department of Microbiology and Immunology, University of California San Francisco
Howard Hughes Medical Institute


  1. malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 2011;8:e1000402.View ArticleGoogle Scholar
  2. Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre M-E, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci USA. 2014;111:E5455–62.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Guler JL, Freeman DL, Ahyong V, Patrapuvich R, White J, Gujjar R, et al. Asexual populations of the human malaria parasite, Plasmodium falciparum, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications. PLoS Pathog. 2013;9:e1003375.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Wu W, Herrera Z, Ebert D, Baska K, Cho SH, DeRisi JL, et al. A chemical rescue screen identifies a Plasmodium falciparum apicoplast inhibitor targeting MEP isoprenoid precursor biosynthesis. Antimicrob Agents Chemother. 2015;59:356–64.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Lehane AM, Ridgway MC, Baker E, Kirk K. Diverse chemotypes disrupt ion homeostasis in the malaria parasite: diverse chemotypes disrupt Plasmodium ion regulation. Mol Microbiol. 2014;94:327–39.View ArticlePubMedGoogle Scholar
  6. Flannery EL, McNamara CW, Kim SW, Kato TS, Li F, Teng CH, et al. Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. ACS Chem Biol. 2015;10:413–20.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TNC, Willis P. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS ONE. 2013;8:e62906.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Li J, McConkey GA, Rogers MJ, Waters AP, McCutchan TR. Plasmodium: the developmentally regulated ribosome. Exp Parasitol. 1994;78:437–41.View ArticlePubMedGoogle Scholar
  9. Jackson KE, Habib S, Frugier M, Hoen R, Khan S, Pham JS, et al. Protein translation in Plasmodium parasites. Trends Parasitol. 2011;27:467–76.View ArticlePubMedGoogle Scholar
  10. Shastry M, Nielsen J, Ku T, Hsu MJ, Liberator P, Anderson J, et al. Species-specific inhibition of fungal protein synthesis by sordarin: identification of a sordarin-specificity region in eukaryotic elongation factor 2. Microbiology. 2001;147:383–90.View ArticlePubMedGoogle Scholar
  11. Baragaña B, Hallyburton I, Lee MCS, Norcross NR, Grimaldi R, Otto TD, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522:315–20.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Ferreras A, Triana L, Correia H, Sánchez E, Herrera F. An in vitro system from Plasmodium falciparum active in endogenous mRNA translation. Mem Inst Oswaldo Cruz. 2000;95:231–5.View ArticlePubMedGoogle Scholar
  13. Bhaskaran S, Butler JA, Becerra S, Fassio V, Girotti M, Rea SL. Breaking Caenorhabditis elegans the easy way using the Balch homogenizer: an old tool for a new application. Anal Biochem. 2011;413:123–32.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA. 2008;105:9059–64.View ArticlePubMedPubMed CentralGoogle Scholar
  15. ChEMBL Databases. Accessed 15 Dec 2015.
  16. Caro F, Ahyong V, Betegon M, DeRisi JL. Genome-wide regulatory dynamics of translation in the Plasmodium falciparum asexual blood stages. Elife. 2014;3:e04106. doi:10.7554/eLife.04106.View ArticleGoogle Scholar


© Ahyong et al. 2016


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.